anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will further examine a treatment plan for adolescents with autism spectrum disorderS (ASD) and anxiety. Many children who have an autism spectrum disorder experience substantial anxiety that can cause impairment above that of an ASD alone. Few studies have examined effective treatment options for anxiety in this population. In typically developing youth, Cognitive Behavioral Therapy (CBT) is considered the gold standard for treating anxiety. But, in order to address the unique needs of children with ASD, this study utilizes a modified CBT treatment plan which includes social skills and parent training. In our past studies, this cognitive-behavioral treatment plan has been effective in kids with ASD and anxiety compared to kids who did not receive any treatment.The current study compares this modified treatment plan to other treatment options in the community. The experimental component of this study is being assigned to 1 of 2 groups. The first group will receive CBT immediately for a period of 16 weeks. The second group will have to wait 16 weeks before receiving CBT. During this time period, children may receive any other services in the community. Overall, all adolescents receive the same type of therapy; it's matter of whether he/she receives it immediately or after a wait period. Sixteen weekly sessions comprise CBT. All therapy and assessments associated with this study will be free of charge.
PURPOSE OF REVIEW: Obesity is an overwhelmingly common medical entity seen in the adult population. A growing body of research demonstrates that there is a significant relationship between child maltreatment and adult obesity.
RECENT FINDINGS: Emerging research demonstrates a potential dose-response relationship between various types of child abuse and adulthood BMI. Recent work also explores the potential role of the hypothalamic-pituitary-adrenal (HPA) axis, and other hormonal mediators such as sex-hormone binding globulin and leptin. There are also studies that suggest factors such as depression and socioeconomic and environmental influences mediate this relationship. Comorbidities that have been reported include cardiovascular and metabolic disease, diabetes, and insulin resistance. Preliminary work also demonstrates potential gender and racial disparities in the effect of abuse on adulthood obesity. In this narrative review, we summarize the existing work describing the different child maltreatment types (physical, sexual, emotional, verbal, and child neglect) and their relation to adult obesity, what is known about a potential dose-response relationship, potential mediators and pathophysiology, comorbidities, and preliminary work on gender and racial/ethnic disparities. We review the limited data on interventions that have been studied, and close with a discussion of implications and suggestions for clinicians who treat adult obesity, as well as potential future research directions.
The present invention relates to an anti-inflammatory agent containing, as an active ingredient, (E)-1-(2-(2-nitro vinyl)phenyl)pyrrolidine (NVPP) as an inhibitor of TRIF-dependent signaling pathway induced by toll-like receptors (TLRs). The TLRs perform an important role in the recognition of many photogenic molecule patterns, and induce a congenital immune response. The recognition of bacterial factors by TLRs suggests MyD88 and (TRIF)-dependent downstream signaling pathways. As described above, the present inventors synthesized (E)-1-(2-(2-nitro vinyl)phenyl)pyrrolidine (NVPP) containing nitrovinyl-phenyl and pyrrolidine. In order to evaluate the potential of NVPP as a therapeutic agent, the signaling induction effect of TLRs through TRIF-dependent pathway induced by lipopolysaccharide (LPS), polyriboinosinic polyribocytidilic acid (Poly[I:C]) was monitored. NVPP inhibits activation of an interferon induced gene, such as interferon induced protein-10, and inhibits phosphorylation of NF-kB, interferon regulation factor, and interferon regulation factor 3, induced by LPS or Poly[I:C]. This result suggests that NVPP regulates the TRIF-dependent signaling pathway of TLRs, and thus can be developed as an effective potential therapeutic agent for chronic inflammatory disease.
ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
OBJECTIVE: A variety of unhealthy sleep behaviors have been shown to be associated with an increased risk of urologic cancers. However, little is known about the association between the overall sleep patterns and urologic cancers. To prospectively investigate the associations between a healthy sleep pattern and the risks of urologic cancers, including bladder cancer (BCa) and renal cell carcinoma (RCC).
METHODS: In this prospective cohort study, 377,144 participants free of cancer at baseline were recruited from the UK Biobank. Data on sleep behaviors were collected through questionnaires at recruitment. The incident urologic cancer cases were determined through linkage to national cancer and death registries. We established a healthy sleep score according to five sleep traits (sleep duration, chronotype, insomnia, snoring, and daytime sleepiness). Cox proportional hazard regression models were used to calculate the adjusted hazard ratios and 95% confidence intervals to assess the relationship between the healthy sleep score and the risk of urologic cancers.
RESULTS: During a median of ≥9 years of follow-up, we identified 1986 incident urologic cancer cases, including 1272 BCa cases and 706 RCC cases. Compared with the participants with a poor sleep pattern (score of 0-2), the multivariable-adjusted hazard ratio and 95% confidence interval were 0.85 (0.75 to 0.96) for urologic cancers, 0.80 (0.68 to 0.93) for BCa, and 0.91 (0.74, 1.12) for RCC, respectively, for those with the healthier sleep pattern (score of 4-5).
CONCLUSION: Our results indicate that a healthy sleep pattern is associated with lower risks of urologic cancers.
Disclosed is a polymannuronate composition including polymannuronate having molecular weight from about 4,000 to about 500,000 in a high purity. The composition can be used in producing nutritional compositions such as functional foods and health aids. Also, the composition can be used in a pharmaceutical composition along with a pharmaceutical carrier. The composition has various effects, including controlling serum lipids, preventing hyperlipidemia, preventing obesity, preventing diabetes, enhancing functions of liver, expelling heavy metals from a body, etc. Further disclosed is a process to producing the polymannuronate composition, in which alginate is hydrolyzed and then the polymannuronate components are isolated. Further disclosed herein is a composition produced by that process. In the hydrolysis, an organic acid is preferably used, and the isolation of the polymannuronate involves adjustment of pH of the resulting mixture of the hydrolysis.
We aimed to determine the minimal clinically important difference (MCID) in pain severity and agreement between the visual analog scale (VAS) and the verbal numeric rating scale (NRS) in people with sickle cell disease (SCD) experiencing an acute vaso-occlusive episode in the emergency department. In the COMPARE-VOE trial (NCT03933397), participants were administered the VAS (0-100), NRS (0-100), and descriptor scale (a lot better, a little better, same, a little worse, much worse) every 30 minutes while in the emergency department. We analyzed data from 100 participants (mean age 30.2 years; 61% female). We calculated the mean differences and 95% confidence intervals (CIs) between current and preceding scores when the participant reported a little worse or a little better pain for each scale (255 VAS and 150 NRS observations) to assess the MCID for the VAS and NRS. Pearson correlation and the Bland-Altman method were used to assess the agreement among 411 paired VAS and NRS observations. Our results indicated that the MCID for the VAS was 8.77 mm (95% CI: 7.43 mm, 10.83 mm) and the NRS was 8.29 (95% CI: 6.47, 11.60). The VAS and NRS scales had a correlation of .88 (P < .001). The Bland-Altman method indicated a mean difference of -4.6 ± 1.96 and the 95% limits of agreement ranged from 20 to -29. Despite high correlation, there was considerable variability of agreement between the VAS and NRS scales, indicating that these scales are not interchangeable to assess pain during a vaso-occlusive event. PERSPECTIVE: The MCID in pain severity for individuals with a SCD vaso-occlusive episode using the VAS (8.77 mm) is lower than previously reported, and the MCID for NRS was 8.29. The agreement between the VAS and NRS was determined and the scales cannot be used interchangeably to measure SCD pain intensity.
Spinal surgery can be associated with significant intraoperative blood loss which may lead to various complications. As the number of patients undergoing spinal surgery increases over time, accurate and effective hemostasis becomes critically important. Despite various surgical hemostatic techniques, conventional interventions such as compression, suture, ligation, and heat-generating cautery, are not suitable for osseous and epidural venous plexus bleeding during spinal procedures. Therefore, a variety of hemostatic agents have been developed to promote hemostasis. As they differ in terms of mechanism, form, application and potential adverse reactions, it is important to understand the natural features of existing agents. Here we comprehensively review currently available topical hemostatic agents from different sources and summarize their mechanisms of action, applications, and current or potential utilization in spinal surgery. We found hemostatic agents from different sources exert hemostatic actions through different mechanisms. In addition, topical hemostatic agents play various roles in spinal surgery including as hemostatic agent, dura mater repair, drug-carrier, skin closure, and fibrosis prevention. Compressive neurological complications are the most common complications of these hemostatic agents. Therefore, optimal use in spinal environments should match their features, indications, and efficacy with clinical conditions.
PCT No. PCT/AU94/00440 Sec. 371 Date Apr. 12, 1996 Sec. 102(e) Date Apr. 12, 1996 PCT Filed Aug. 2, 1994 PCT Pub. No. WO95/04030 PCT Pub. Date Feb. 9, 1995The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non DIFFERENCE steroidal anti DIFFERENCE inflammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.
BACKGROUND: Cardiac dysfunction due to cardiotoxicity from anthracycline chemotherapy is a leading cause of morbidity and mortality in childhood cancer survivors (CCS), and the cumulative incidence of cardiac events has continued to increase. This study identifies an adequate indicator of cardiac dysfunction during long-term follow-up.
PROCEDURE: In total, 116 patients (median age: 15.5 [range: 4.7-40.2] years) with childhood cancer who were treated with anthracycline were divided into three age groups for analysis (C1: 4-12 years of age, C2: 13-18 years of age, C3: 19-40 years of age), and 116 control patients of similar ages were divided into three corresponding groups (N1, N2, and N3). Layer-specific strains were assessed for longitudinal strain (LS) and circumferential strain (CS). The total and segmental intraventricular pressure gradients (IVPG) were also calculated based on Doppler imaging of the mitral inflow using Euler's equation.
RESULTS: Conventional echocardiographic parameters were not significantly different between the patients and controls. All layers of the LS and inner and middle layers of the basal and papillary CS in all ages and all IVPGs in C2 and C3 decreased compared to those of corresponding age groups. Interestingly, basal CS and basal IVPG in CCS showed moderate correlation and both tended to rapidly decrease with aging. Furthermore, basal IVPG and anthracycline dose showed significant correlations.
CONCLUSIONS: Basal CS and total and basal IVPGs may be particularly useful indicators of cardiotoxicity in long-term follow-up.
Accumulating evidence suggests a link between vascular endothelial growth factor (VEGF), erectile dysfunction (ED), and metabolic syndrome (Mets), possibly because VEGF can alter the physiological pathways involved in the regulation of endothelial cell proliferation. This study aimed to investigate the genetic susceptibility of VEGF 2578C>A polymorphism to the development of ED and Mets. Collected data included five-item International Index of Erectile Function (IIEF-5), components of Mets, and VEGF 2578C>A polymorphism. A total of 596 subjects from Kaohsiung with a mean age of 55.5 years were enrolled, data collection was done at our hospital. Individuals carrying the VEGF 2578 A allele (CA+AA genotypes) demonstrated a higher prevalence of ED compared to those with the CC genotype, with an adjusted odds ratio (OR) of 1.582 (95% confidence interval [95% CI] = 1.123-2.227, p value = 0.009) in multivariate binary regression analysis. Similarly, individuals carrying the VEGF 2578 A allele showed a higher prevalence of Mets compared to those with the CC genotype, with an adjusted OR of 2.461 (95% CI = 1.491-4.064, p value < 0.001). Furthermore, A allele carriers had significantly lower IIEF-5 scores and a higher number of Mets components compared to those with the C allele (P value < 0.001, respectively). In conclusion, VEGF 2578 A allele carriers are at a greater risk of both Mets and ED, suggesting that the VEGF 2578C>A polymorphism may serve as a common genetic susceptibility factor in the development of both disorders. Further research is warranted to evaluate the mechanisms underlying this association.
Improved sample container embodiments are provided for containing and supporting tissue samples during imaging. These sample containers support the samples to prevent distortion due to gravity and/or forces applied on the sample by elements of the container itself. Images generated for the samples thus more accurately reflects the geometry, composition, and orientation of the samples in the body prior to their removal. Such sample containers can include compliant cushions, which may be formed from sheets of material rather than solid volumes of foam or other materials. Such a reduction in cushion material proximate to the sample can result in improved sample imaging. The sample container can also be composed of fluid-impermeable materials to prevent absorption of fluid from the sample, reducing sample deformation and also reducing the imaging of the container material due to absorption of fluid from the sample.
A coupling mechanism which supports an inventory divider within a storage bin. The coupling mechanism comprises a joint extension and a holding mechanism. The coupling mechanism is coupled to an interior wall of a supply bin. An inventory divider is inserted into the joint extension and is rotated within the joint extension between and upper and lower position within the storage bin. The holding mechanism of the coupling mechanism retains the inventory divider in the upper position, dividing the storage bin into two compartments. By retaining the inventory divider with a holding mechanism that is not directly connected to the bin, the wear on the holding mechanism is substantially reduced and the inventory divider is more secure.
A transparent or translucent cosmetic composition in the form of a water-in-oil emulsion is provided. The composition includes an aqueous phase at a concentration, by weight, of about 50%-90%, based upon weight of the composition. The aqueous phase includes at least one amphiphilic compound selected from the group consisting of urea, sodium 5-oxo-2-pyrrolidinecarboxylate (sodium PCA), hydroxyethyl urea, nicotinamide, sodium citrate, ascorbic acid, or combinations thereof. The at least one amphiphilic compound is at a concentration, by weight, of about 2% to about 50%, based upon weight of the composition. The composition includes an oil phase comprising at least one water-in-oil emulsifier at a concentration, by weight, of about 1%-25%, based upon weight of the composition. The water-in-oil emulsion is a transparent or translucent composition.
The DOMINO study is a randomized, double-blind, multi-center, futility study of minocycline in patients with HD. Subjects will be randomized (3:1) to one of the two study arms: (1) the group that receives active minocycline (100 mg po b.i.d.), and (2) the group that receives placebo. Subjects will be enrolled over an approximate six-month period and remain on blinded study drug for 18 months. The primary analysis will involve a comparison of the change over time in TFC between the minocycline group and a fixed value determined from historical control data. A placebo group will also be included to facilitate blinding and to permit a descriptive assessment of the validity of the assumed change over time in historical controls.
The present invention provides a recombinant monoclonal antibody against REGgamma protein, which comprises a heavy chain variable region and a light chain variable region. The nucleotide sequence and the amino acid sequence of the heavy chain variable region are respectively shown in SEQ ID NO. 1 and SEQ ID NO. 3, and the nucleotide sequence and the amino acid sequence of the light chain variable region are respectively shown in SEQ ID NO.2 and SEQ ID NO. 4. The invention co-transfects the eukaryotic expression plasmid carrying the recombinant antibody gene of the light chain and the heavy chain into HEK293T cells for expression and purification. The monoclonal antibody of the REGgamma C-terminal region is used as a control antibody, and the performance of the antibody is evaluated by using WesternBlot, cell immunofluorescence, immunohistochemical techniques and ELISA techniques. The result shows that the recombinant monoclonal antibody has the advantages of strong specificity, high sensitivity, strong stability, no dependence on animal production, suitability for quantitative production and the like, and provides an effective tool for taking the over-expressed REGgamma protein as a diagnosis and treatment target of diseases.
Adult ARDS (according to Berlin definition) patients were enrolled in the trial. The diagnostic criteria included (a) within one week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging showing that bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (c) respiratory failure not fully explained by cardiac failure or fluid overload; and (d) arterial partial pressure of oxygen / fraction of inspiration oxygen (PaO2/FiO2 ratio, P/F ratio) less than or equal to 300 mmHg.
This is an open-label, Phase 1, outpatient, dose escalation study of Pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. In the first part of the study, escalating doses of Pritumumab of 1.6, 4.8, 8.0, 12.0, and 16.2 mg/kg will be administered in a sequential, safety-driven manner to eligible patients according to standard 3+3 scheme, as an 1-hour IV infusion on Days 1, 8, 15, and 22 of each 28-day treatment cycle. The dose levels may be modified upon obtained results. Once the maximum tolerated dose (MTD) is determined, an expansion cohort including 6-12 patients in selected tumor type at a dose equal or below to MTD is planned to determine the recommended Phase 2 dose (RP2D). A total of 42 patients may be administered with Pritumumab in this study.

Patients will be treated with Pritumumab for a maximum of 6 cycles or until cancer progression or unacceptable toxicity. Patients will be followed after treatment completion every four months or until death or lost to follow-up. Standard clinical, laboratory and functional assessments will be employed to monitor for safety, tolerability and tumor response, including blood sampling for clinical biochemistries, pharmacokinetics, CSF and tissue samples, at frequency specified by the protocol. Patient-reported outcomes will also be assessed.
Kabat technique will be performed for 15 min along with baseline treatment will be given to Group A. They will have 45 min-1 hour session thrice a week in duration of six weeks.
The invention relates to the field of cosmetics, and in particular relates to a composition with the efficacies of inhibiting bacteria and diminishing inflammation. The composition is prepared from the following components in parts by weight: 3-5 parts of herba Saponaria officinalis. extract, 0.1-0.3 part of allantoin, 2-6 parts of polydimethylsiloxane, 0.1-1 part of tocopheryl acetate, 0.3-2 parts of a water-soluble polymer, 10-25 parts of a skin emollient, 0.01-0.15 part of a chelating agent, 10-20 parts of a surfactant, 0.1-1 part of a neutralizer, 3-10 parts of a skin conditioner, 0.1-1.5 part of a preservative, 0.1-0.2 part of essence, and 30-75 parts of deionized water. The composition provided by the invention can inhibit bacteria and diminish inflammation, can rapidly repair the damaged skin, and enables the skin to be compact and elastic. For the composition, the herba Saponaria officinalis. extract is taken as the acne-removing component, and the obtained product is natural, mild and non-toxic, is low in irritation, and has the great social value and economic benefit.
Phenylephrine is the active moiety. Metabolites are inactive at both the α-1 and α-2 adrenergic receptors. Following parenteral administration of phenylephrine hydrochloride, increases in systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, and total peripheral vascular resistance are observed. The onset of blood pressure increase following an intravenous bolus phenylephrine hydrochloride administration is rapid and the effect may persist for up to 20 minutes. As mean arterial pressure increases following parenteral doses, vagal activity also increases, resulting in reflex bradycardia.

Most vascular beds are constricted, including renal, splanchnic, and hepatic.